Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The provided statements about tardive dyskinesia risk/warnings/duration/stop largely align with the supplied GIMOTI label excerpts (risk increases with duration/cumulative dose, discontinue if TD develops, duration limit ~12 weeks, contraindication in history of TD). However, the included claims set provided do not explicitly cover some key label elements in the specific direction requested (e.g., explicit 'immediately discontinue' and the 12-week limit), so overall alignment is partial.
Category Scores
Accurate Statements
The risk of serious neurologic side effects can increase with longer exposure.
SECTION 5.1: “The risk of developing TD and the likelihood that TD will become irreversible increases with duration of treatment and total cumulative dosage.”
Unsupported Statements
More serious movement-related reactions and other neurologic effects can occur with longer use or higher doses.
Label excerpt provided specifically links TD risk/irreversibility to duration and total cumulative dosage; it does not explicitly state 'higher doses' as a separate factor in the provided TD excerpts.
Contradictions
Important Omissions
Explicit instruction to 'Immediately discontinue GIMOTI' when signs/symptoms of TD develop.
Importance:
Moderate
Explicit duration limit: avoid total duration longer than 12 weeks (and monitor if longer-term use unavoidable).
Importance:
Moderate
Explicit contraindication language: GIMOTI contraindicated in patients with a history of TD (and dystonic reaction).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Key label actions/limits for TD risk mitigation (immediate discontinuation upon TD development; explicit 12-week duration limit; explicit contraindication criteria) are not explicitly stated in the provided claim set, which could reduce alignment with on-label risk management.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Missing or non-explicit inclusion of the label’s specific TD risk-mitigation instructions (immediate discontinuation, explicit 12-week limit, and contraindication wording).
Suggested Improvement
Add label-accurate specifics: (1) immediately discontinue upon TD signs/symptoms, (2) avoid total metoclopramide product duration >12 weeks and monitor if unavoidable, and (3) explicitly state contraindication in history of TD (and dystonic reaction to metoclopramide).